9 Analysts Assess Surgery Partners: What You Need To Know
Portfolio Pulse from Benzinga Insights
Surgery Partners (NASDAQ:SGRY) has been evaluated by 9 analysts over the past three months, with ratings ranging from bullish to bearish. The average 12-month price target is $44.44, slightly down from the previous $44.67. The company has shown a 14.16% revenue growth rate but struggles with profitability, as indicated by its negative net margin, ROE, and ROA. Analysts maintain varied ratings, with some maintaining 'Buy' or 'Overweight' stances.
October 04, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Surgery Partners has received mixed analyst ratings, with a slight decrease in the average price target to $44.44. The company shows strong revenue growth but faces profitability challenges, as indicated by negative net margin, ROE, and ROA.
The mixed analyst ratings and slight decrease in price target suggest a neutral short-term impact on SGRY's stock price. While the company shows strong revenue growth, its profitability challenges may concern investors, balancing the overall sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100